Crohn's Disease. The What, When, and Why of Treatment
|
|
- Carol Clarke
- 5 years ago
- Views:
Transcription
1 Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be discussing off label use of several medications to treat Crohn s disease 1
2 Nancy 30 year old female presents with 3 month history of perianal pain and drainage without change in stool habits Treated empirically with metronidazole with only minimal improvement Colonoscopy with TI intubation and biopsy show evidence of patchy colitis with rectal involvement c/w Crohn s disease FH: positive for Crohn s in brother PE: Normal except rectal exam which showed 3 Nancy 4 2
3 Cumulative Incidence of Crohn s Fistulas Schwartz DA, et al. Gastroenterology. 2002;122(4): Frequency of Perianal Fistulas According to Anatomic Location of Bowel Involvement Colon only (without rectal involvement) 41% Small intestine only 12% Rectum only 92% Combined ileocolic involvement 15% Hellers G, et al. Gut. 1980;21(6):
4 Park s Classification of Perianal Fistulas Extrasphincteric External anal sphincter Trans sphincteric Superficial Parks AG. Br Med J. 1961;1(5224): Intersphincteric Suprasphincteric 7 Simple vs Complex Fistula Simple Complex Sandborn WJ, et al..gastroenterology. 2003;125(5):
5 Diagnostic Options Used in the Classification of Perianal CD History Physical Exam Imaging Fistulography CT MRI Endorectal ultrasound 9 What Happens When Fistulas are Missed at Time of EUA? N=71 52% of patients needed repeat surgery in cases where surgery and MRI disagreed Fistula recurrence was always at site predicted by MRI Buchanan G, et al. Lancet. 2002;360(9346):
6 Does Controlling Fistula Healing Make a Difference? N = 32 Percent of Patients 100% 80% 60% 20% 0% Fistula Recurrence 79% 44% Inflix Only EUA Before Inflix 120% 100% 80% 60% 20% 0% Response to Treatment 100% 83% Inflix Only EUA Before Inflix p=0.014 p=0.001 Requeiro M, et al. Inflamm Bowel Dis. 2003;9(2): Setons Prevent Abscesses by Preventing Premature Closure of Fistula Tract Rosen, MJ. Clin Gastroenterol Hepatol. 2010;8(1):
7 Medical Therapies Antibiotics (metronidazole, ciprofloxacin) Antimetabolites Azathioprine 6 mercaptopurine Methotrexate Cyclosporine Tacrolimus Biologic Agents Infliximab Adalimumab Certolizumab 13 Antibiotics Metronidazole: typical dose is mg po tid/qid, improvement seen after 6 8 weeks Most studies are open label Largest study conducted by Bernstein et al 1 21 patients studied, healing seen in 83% Three other studies found healing rate of 34 50% 2 5 Fistulas re occur once medicine is stopped Adverse events include metallic taste, glossitis, nausea and a distal peripheral sensory neuropathy 1. Bernstein LH, et al. Gastroenterology. 1980;79(2): Schneider MU, et al. Dtsch Med Wochenschr. 1981;106(36): Jakobovits J, et al. Am J Gastroenterol. 1984;79(7): Schneider MU, et al. Dtsch Med Wochenschr. 1985;110(45): Brandt LJ, et al. Gastroenterology. 1982;83(2):
8 Antibiotics Fistula Response Percent Fistula Response at 10 weeks p= % 13% 10 0 N=10 N=7 N=8 Cipro Metronidazole Placebo Thia KT, et al. Inflamm Bowel Dis. 2009;15(1): Azathioprine / 6MP Five controlled trials were summarized in a metaanalysis 1 22 / 41 (54%) of patients who received AZA /6 MP responded vs. 6 / 29 (21%) who received placebo Pooled odds ratio was 4.44 in favor of fistula healing No dedicated trials post hoc subgroups Pearson DC, et al. Ann Intern Med. 1995;123(2):
9 Azathioprine/6-Mercaptopurine Toxicity Nausea Allergic reactions (fevers, arthralgias) Pancreatitis Bone marrow depression Drug induced hepatitis Infectious complications Lymphoma, non melanoma skin cancer Present DH, et al. N Engl J Med. 1980;302(18): Lymphoma Risk and Thiopurines CESAME cohort 19,486 patients in France with IBD Outcomes based on drug exposure 23 new cases of lymphoproliferative disorders diagnosed HR 5.28 ( ) for lymphoproliferative disorder with thiopurine exposure Beaugerie L, et al. Lancet. 2009;374(9701): Kotlyar K, et al. Am J Gastroenterol. 2010; 105;S
10 Minimizing Toxicity from Thiopurines Check TPMT first to rule out those with low enzyme activity Schedule regular CBC, liver enzymes Educate patient on symptoms to watch for Dosing at night anecdotally alleviates some complaints of nausea Vaccinate patients for age appropriate diseases prior to initiation Kane S. Curr Gastroenterol Rep. 2010;12(6): Tacrolimus (FK-506) 50% 30% 20% 10% 0% p= % 8% Tacrolimus Placebo Improved Double blinded study n=48 Randomized to receive 0.20 mg/kg/day for 10 weeks Primary endpoint: improvement defined as closure of > 50% fistulas and maintenance of closure for >4 weeks Only 10% had closure of all fistulas Sandborn WJ, et al. Gastroenterology. 2003;125(2):
11 Infliximab for Crohn s Perianal Fistulas 80% 60% 20% 0% 68% 56% 26% Placebo 5 mg/kg 10mg/kg P<0.001 P=0.041 Initial fistula response to infliximab n=94 Primary endpoint: > 50% reduction in open fistulas Present DH, et al. N Engl J Med. 1999;340(18): Accent II: Infliximab for Maintaining Fistula Closure Percent Placebo 36 5 mg/kg Percent of patients maintaining complete fistula closure n= weeks Primary endpoint: > 50% reduction in open fistulas p= Sands BE, et al. N Engl J Med. 2004;350(9):
12 Adalimumab: Complete Healing of Draining Fistulas 60% 50% 30% 20% 10% 0% 48% 39% 29% 14% Placebo 40 mg eow 40 mg weekly Both groups Weeks 26 and 56: Randomized responders in CHARM trial n=70 Colombel JF, et al. Gastroenterology. 2007;132: Proportion of Fistula Responders with Fistula Closure Percent 80% 70% 60% 50% 30% 30.8% 67.7% Week 26 on Certolizumab Pegol PRECiSE 2 subgroup 20% 10% 0% Placebo Certolizumab Schreiber S, et al. Aliment Pharmacol Ther. 2011;33(2):
13 Proportion of Fistula Responders with Fistula Closure 35% 30% 25% 20% 15% 10% 5% 0% p= % 36% Placebo CZP 400 mg Q4w N=13 N=15 Week 26 on Certolizumab Pegol PRECiSE 2 subgroup Schreiber, et al. Presented at: Crohn's and Colitis Foundation of America 2008 Advances in Inflammatory Bowel Diseases; Hollywood, Florida; December 4-7, Abstract O Schreiber S, et al. Aliment Pharmacol Ther. 2011;33(2): Anti-TNF Agents: Adverse Events Immunogenicity Infection Granulomatous (TB, histo, Listeria) Viral, fungal Autoimmunity Lymphoproliferative dx? Neoplasm Skin Pediatric tumors Psoriaform lesions Demyelinating disorders true causal??? Worsen or de novo congestive heart failure Hepatotoxicity (rare) true causal?? Stallmach A, Hagel S, Bruns T. Best Pract Res Clin Gastroenterol. 2010;24(2):
14 Minimizing Toxicity for Anti-TNF Therapy Rule out evidence for TB prior to initiation If immunocompromised, PPD and Quantiferon may be negative Rule out active infection prior to initiation Abscess C difficile CMV Vaccination for age appropriate diseases Kane S. Curr Gastroenterol Rep. 2010;12(6): Minimizing Toxicity for Anti-TNF Therapy Check serologies for Hepatitis B Assess for signs/symptoms of: Uncontrolled heart failure Demyelinating disorders (MS) Skin cancers/suspicious moles Kane S. Curr Gastroenterol Rep. 2010;12(6):
15 Approach to the Crohn s Disease Patient with a Perianal Fistula 1. History and physical exam 2. Endoscopy to assess activity of Crohn s disease 3. Imaging study (EUS or MRI) to delineate perianal disease process 4. Exam under anesthesia (EUA) Simple Fistula Without Rectal Inflammation Simple Fistula With Rectal Inflammation Complex Fistula Antibiotics and AZA/6 MP Consider anti TNF Antibiotics, AZA/6MP and Anti TNF (Consider monitoring healing with repeat imaging study) 1. Seton placement 2. Antibiotics, AZA/6 MP and Anti TNF (Consider monitoring healing with repeat imaging study) Treatment Failure Treatment Success Treatment Failure Treatment Success Treatment Failure Treatment Success 1. Fistulotomy 2. Consider fibrin glue, fistula plug or endorectal advancement flap 3. If 1 or 2 fails, treat as complex fistulizing process Continue maintenance AZA/6 MP and Anti TNF (if started) Treat as complex fistulizing process Continue maintenance AZA/6 MP & Anti TNF Consider Tacrolimus in selected pts Proctectomy 1. Remove seton 2. Continue maintenance AZA/6 MP and Anti TNF 29 Nancy: Follow-Up Patient underwent rectal EUS which confirmed trans sphincteric fistula with associated abscess (complex fistula) Received appropriate vaccinations Underwent EUA with seton placement and started azathioprine, 2.5 mg/kg/day (TPMT nl) and an anti TNF Setons removed 4 months later once rectal EUS demonstrated an inactive fistula Continued maintenance azathioprine and anti TNF 30 15
Epidemiology / Morbidity
Perianal Crohn s Disease: Current Treatment Approach David A Schwartz, MD Director, Inflammatory Bowel Disease Center Vanderbilt University Medical Center Epidemiology / Morbidity Hellers et al, Gut 1980
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationPD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc. Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Konservative Behandlungsmöglichkeiten?
PD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Fisteln bei M. Crohn : Konservative Behandlungsmöglichkeiten? INTERDISZIPLINÄRE VISZERALE CHIRURGIE
More informationModern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions
Modern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions Rami Ismail, Pharm.D., BCPS, BCCCP, CACP Lead Clinical staff Pharmacist, Cleveland Clinic Abu Dhabi Disclosure Information
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Francis A. Farraye, MD, MSc, FACG Professor of Medicine Clinical Director, Section of Gastroenterology Boston University School of Medicine Boston,
More informationPerianal Fistula of Crohn s Disease
Case 3 Perianal Fistula of Crohn s Disease A 16 year-old boy referred by surgeon due to perianal fistula since 6mo ago CC=perianal pain History of intermittent non-bloody diarrhea and mild abdominal pain
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationCorporate Presentation
Corporate Presentation The treatment of perianal December fistula 2015in Crohn s disease patients Key Opinion Leader Event 8 th May 2017 Forward-Looking Statements This document does not constitute or
More informationOf Treatment For Inflammatory Bowel Diseases
Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38545 holds various files of this Leiden University dissertation. Author: Molendijk, Ilse Title: Mesenchymal stromal cell therapy for Crohn's disease :
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationSurgical Management of IBD in the Age of Biologics
Surgical Management of IBD in the Age of Biologics Lisa S. Poritz, M.D Associate Professor of Surgery Division of Colon and Rectal Surgery Objectives Discuss surgical management of IBD When to operate
More informationAdverse Events From Biologic Agents in IBD
Adverse Events From Biologic Agents in IBD David A. Schwartz, MD, FACG Director, Inflammatory Bowel Disease Center Professor of Medicine Vanderbilt University Medical Center Case Page 1 of 24 28 yo with
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationNEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL
NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationCrohn s
Crohn s Disease David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition Co-Director, Digestive Diseases Center @IBDMD Disclosures
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationIBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh
IBD Biologicals and Novel therapeutic regimes Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh 1 Treatment aims in IBD Traditional treatment goals of IBD Control of symptoms?improvement
More informationCx601 ADMIRE-CD Top-Line Results Webcast. 24 August 2015
Cx601 ADMIRE-CD Top-Line Results Webcast 24 August 2015 1 Cx601 ADMIRE-CD Top-Line Results Webcast Speakers Mr Eduardo Bravo, Chief Executive Officer Dr Julián Panés, Head of Gastroenterology Department,
More informationEffect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series
CASE REPORT Effect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series Kaori Fujiwara, Takuya Inoue, Naoki Yorifuji, Munetaka Iguchi, Taisuke Sakanaka, Ken Narabayashi,
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationThe Effect of Medical Treatment on Patients with Fistulizing Crohn s Disease: A Retrospective Study
ORIGINAL ARTICLE The Effect of Medical Treatment on Patients with Fistulizing Crohn s Disease: A Retrospective Study Norimitsu Uza, Hiroshi Nakase, Satoru Ueno, Satoko Inoue, Sakae Mikami, Hiroyuki Tamaki,
More informationRisk = probability x consequence
Explaining Risks of IBD Therapy to Parents and Patients December 4, 2009 CCFA Advances in IBD Hollywood, FL Corey A. Siegel Assistant Professor of Medicine, Dartmouth Medical School Director, Dartmouth-Hitchcock
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationManagement of complex perianal Crohn s disease
REVIEW ARTICLE Annals of Gastroenterology (2017) 30, 1-12 Management of complex perianal Crohn s disease Lara Aguilera-Castro, Carlos Ferre-Aracil, Ana Garcia-Garcia-de-Paredes, Enrique Rodriguez-de-Santiago,
More informationAnti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients
Alimentary Pharmacology and Therapeutics Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients A. B. Mohabbat*, W. J. Sandborn, E. V. Loftus Jr, R. H. Wiesner
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationCommunicating with the IBD Patient: How to convey risks and benefits
Communicating with the IBD Patient: How to convey risks and benefits October 30, 2011 ACG Postgraduate Course National Harbor, Maryland Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationLaboratory Testing: Medication Dependent. The Newly Diagnosed Patient. Why Talk about This? Lack of Primary Care
Why Talk about This? Lack of Primary Care Health Care Maintenance in the IBD Patient Sunanda Kane, MD MSPH FACG FACP AGAF Mayo Clinic Rochester Many patients with IBD are young and do not have co-morbid
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationet al.. Long-term outcome of perianal fistulizing Crohn s disease treated with infliximab..
Long-term outcome of perianal fistulizing Crohn s disease treated with infliximab. Guillaume Bouguen, Laurent Siproudhis, Emmanuel Gizard, Timothée Wallenhorst, Vincent Billioud, Jean-François Bretagne,
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationPediatric Inflammatory Bowel Diseases
Pediatric Inflammatory Bowel Diseases Michael Stephens, M.D. Denny Sanford Pediatric Symposium November 21 2014, Sioux Falls, SD 2014 slide-1 Disclosures I have nothing to disclose 2014 slide-2 Objectives
More informationUnderstanding Inflammatory Bowel Diseases (IBD):
Understanding Inflammatory Bowel Diseases (IBD): What Every Patient Needs to Know William H Holderman, MD Digestive Health Specialists Tacoma, WA Today s Objectives Define IBD, its potential causes and
More informationSpecial Authorization Drug Products with
Effective August 1, 2008 Summary Special Authorization Drug Products with Changes to Criteria Special Authorization Drug Products with Changes to Criteria Alberta Blue Cross has been advised by Alberta
More informationIBD-Related Lymphoma
IBD-Related Lymphoma Larry Burgart MD Staff Pathologist, Allina Health and Minnesota Gastroenterology Clinical Professor of Pathology, University of Minnesota College of Medicine IBD-Related Lymphoma
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationCrohn s Disease. Resident Lecture 1/17/19
Crohn s Disease Resident Lecture 1/17/19 Objectives Features/Classification of Crohn s Disease Medical Treatment Surgical Indications Surgical Considerations 2 Case 25 yo F presents to your office with
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationI B D. etter than this. isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES
I B D m etter than this isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES What types of people have learned how to manage their IBD? Athletes Musicians Firefighters DOCTORS HEROES Artists Presidents Actors
More informationINNOVATIONS IN TREATMENT OF PERIANAL CROHN DISEASE combined therapy
Dipartimento di Scienze Mediche e Chirurgiche Istituto di Clinica Chirurgica Prof. Aroldo Fianchini Ancona INNOVATIONS IN TREATMENT OF PERIANAL CROHN DISEASE combined therapy Cristina Marmorale PERIANAL
More informationSlide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology
Slide 1 Medications in inflammatory bowel disease a primer for health care providers Athos Bousvaros, MD Associate director Inflammatory Bowel Disease Center Boston Children s Hospital 617 355 2962 Slide
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationTreatment of Crohn s disease-related high perianal fistulas combining the mucosa advancement flap with platelet-rich plasma: a pilot study
Tech Coloproctol (2015) 19:455 459 DOI 10.1007/s10151-015-1311-8 ORIGINAL ARTICLE Treatment of Crohn s disease-related high perianal fistulas combining the mucosa advancement flap with platelet-rich plasma:
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationDiarrhoea for the Acute Physician
Diarrhoea for the Acute Physician STEPHEN INNS GASTROENTEROLOGIST AND PHYSICIAN HUTT VALLEY DHB August 2013 Outline Case History 1 Initial assessment of acute diarrhoea Management of fulminant UC Management
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationDr David Epstein Vincent Pallotti Hospital and University of Cape Town
Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationImproving outcome of Inflammatory Bowel Disease in children
Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University School of Medicine Pediatric Gastroenterology
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationCrohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine
Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight
More informationThe second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations
Journal of Crohn's and Colitis (2010) 4, 63 101 available at www.sciencedirect.com SPECIAL ARTICLE The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationTop 10 Things you need to know about IBD. Suresh Pola, MD Kaiser San Diego
Top 10 Things you need to know about IBD Suresh Pola, MD Kaiser San Diego Top 10 Things to Know: IBD What you can eat How to treat the pain Not all diarrhea is a flare Ways to reduce your risk of getting
More informationPreventive Care and Monitoring of the IBD Patient
Preventive Care and Monitoring of the IBD Patient Francis A. Farraye, MD, MSc, FACG Clinical Director, Section of Gastroenterology Director, Inflammatory Bowel Disease Center Boston Medical Center Professor
More informationTumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More information